KDM1A and acute myeloid leukemia: Preclinical studies with another LSD1 inhibitor GSK2879552 using 150 cancer cell lines, showed that SCLC and acute myeloid leukemia (AML) cell lines were sensitive to growth inhibition by the LSD1 inhibitor [125,126,127].